Search Videos by Topic or Participant
Browse by Series:

Immunotherapy-Related Adverse Events

Panelists: Ivan Marques Borello, MD, Johns Hopkins; Myron S. Czuczman, MD, Roswell Park; Madhav V. Dhodapkar, MBBS, Yale; Dan Douer, MD, MSK 
Published Online: Friday, Jun 26, 2015

For High-Definition, Click
Distinct sets of adverse events (AEs) occur in individuals who are treated with immunotherapies, says Madhav Dhodapkar, MD. Many of these AEs resemble autoimmune diseases, such as autoinflammatory rheumatic disease, dermatologic disease, and endocrinopathies. Early detection of these AEs is essential for a positive outcome, notes Dhodapkar, especially in the context of chimeric antigen receptor (CAR) T-cell therapy.

Treatment with immunotherapy, especially CAR T-cell therapy, may result in very high levels of cytokines, causing a clinical condition that presents with shock-like symptoms, explains Dan Douer, MD. These responses may occur very rapidly and need to be managed promptly. The other main toxicities associated with the rapid release of cytokines result in neurologic side effects, adds Douer. These effects are transient and generally reversible.

Clinical trials evaluating immunotherapies have excluded individuals with preexisting autoimmune diseases. The challenge after these medications gain FDA approval and are available in the community, says Ivan Marques Borrello, MD, is knowing how patients with these preexisting conditions will respond to these new agents.
Slider Left
Slider Right

For High-Definition, Click
Distinct sets of adverse events (AEs) occur in individuals who are treated with immunotherapies, says Madhav Dhodapkar, MD. Many of these AEs resemble autoimmune diseases, such as autoinflammatory rheumatic disease, dermatologic disease, and endocrinopathies. Early detection of these AEs is essential for a positive outcome, notes Dhodapkar, especially in the context of chimeric antigen receptor (CAR) T-cell therapy.

Treatment with immunotherapy, especially CAR T-cell therapy, may result in very high levels of cytokines, causing a clinical condition that presents with shock-like symptoms, explains Dan Douer, MD. These responses may occur very rapidly and need to be managed promptly. The other main toxicities associated with the rapid release of cytokines result in neurologic side effects, adds Douer. These effects are transient and generally reversible.

Clinical trials evaluating immunotherapies have excluded individuals with preexisting autoimmune diseases. The challenge after these medications gain FDA approval and are available in the community, says Ivan Marques Borrello, MD, is knowing how patients with these preexisting conditions will respond to these new agents.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 20th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 24, 20172.0
OncoLogue Case Discussions™: Smoldering Myeloma: To Treat or Not to Treat?Jun 22, 20171.5
Publication Bottom Border
Border Publication